RedHill Biopharma's RHB-204 kills MAP bacteria in lab studies
RDHL•RedHill Biopharma said two laboratory studies found RHB-204 killed MAP bacteria comparably to RHB-104. Comparable activity at lower doses of two active ingredients may reduce toxicity and side effects, the company said.
1. Laboratory study results
RedHill Biopharma announced that two laboratory studies found its Crohn's disease candidate RHB-204 killed MAP bacteria comparably to RHB-104. Comparable activity at lower doses of two active ingredients suggests potential for reduced toxicity and side effects. RHB-204 is ready for Phase 2 development, and the company is pursuing partnerships to advance the program.
